CDXI.US Cardax Inc

Healthcare Pharmaceuticals USA Stocks
0.0001 USD
Close of Oct 6, 2026
0.0001 0.0001
Market cap
USD 80.00
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is CDXI.US undervalued?

Graham number

The Graham number of Cardax Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cardax Inc fundamental analysis

No fundamental analysis for Cardax Inc yet.

Cardax Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cardax Inc

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical …

Full company profile